ArticleJournal of ultrasound2026
CEUS for the diagnosis of acute graft pyelonephritis in renal transplant recipients.
Article in Journal of ultrasound, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAcute graft pyelonephritis (AGPN) is a clinically relevant complication in renal transplant recipients, in whom diagnosis may be challenging because of nonspecific clinical and conventional ultrasound findings. Contrast-enhanced ultrasound (CEUS) enables real-time assessment of renal microvascular perfusion without nephrotoxic contrast agents. This study aimed to evaluate the diagnostic performance of CEUS for detecting AGPN in renal transplant recipients.
methodsThis retrospective single-center study included 66 consecutive renal transplant recipients who underwent CEUS for clinically suspected AGPN. The final clinical diagnosis, based on the integration of clinical, laboratory, microbiological, and available imaging findings, was used as the reference standard. Conventional ultrasound findings and CEUS parenchymal perfusion abnormalities were assessed. Diagnostic performance was evaluated in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and likelihood ratios.
resultsAGPN was confirmed in 21/66 patients (31.8%). Fever was more frequent in patients with AGPN than in those without AGPN (100% vs. 73.3%, p=0.014). On conventional ultrasound, globular graft appearance (14.3% vs. 0%, p=0.029), cortical hyperechogenicity (23.8% vs. 0%, p=0.002), cortical hypoechogenicity (28.6% vs. 4.4%, p=0.010), perirenal fluid collection (38.1% vs. 11.1%, p=0.018), and ureteral wall thickening (42.9% vs. 8.9%, p=0.002) were significantly associated with AGPN. CEUS correctly identified 19/21 AGPN cases, with two false-negative and no false-positive examinations. Sensitivity was 90.5% (95% CI 69.6-98.8%), specificity 100% (95% CI 92.1-100%), PPV 100% (95% CI 82.4-100%), and NPV 95.7% (95% CI 85.5-99.5%).
conclusionCEUS showed high diagnostic accuracy for AGPN in renal transplant recipients. By providing real-time assessment of graft parenchymal perfusion without nephrotoxicity or ionizing radiation, CEUS may represent a valuable complement to conventional ultrasound and potentially reduce the need for contrast-enhanced CT in selected patients. Larger prospective multicenter studies with standardized independent reference standards are warranted.
Indexed as
Identifiers
42799951What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.